MA54087A - Sels cristallins d'un inhibiteur de la kallicréine plasmatique - Google Patents

Sels cristallins d'un inhibiteur de la kallicréine plasmatique

Info

Publication number
MA54087A
MA54087A MA054087A MA54087A MA54087A MA 54087 A MA54087 A MA 54087A MA 054087 A MA054087 A MA 054087A MA 54087 A MA54087 A MA 54087A MA 54087 A MA54087 A MA 54087A
Authority
MA
Morocco
Prior art keywords
kallicrein
inhibitor
plasma
crystalline salts
crystalline
Prior art date
Application number
MA054087A
Other languages
English (en)
French (fr)
Inventor
Yarlagadda S Babu
Yahya El-Kattan
Original Assignee
Biocryst Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70457981&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA54087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocryst Pharm Inc filed Critical Biocryst Pharm Inc
Publication of MA54087A publication Critical patent/MA54087A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44Oxygen and nitrogen or sulfur and nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Food Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA054087A 2018-11-02 2019-11-01 Sels cristallins d'un inhibiteur de la kallicréine plasmatique MA54087A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862754983P 2018-11-02 2018-11-02

Publications (1)

Publication Number Publication Date
MA54087A true MA54087A (fr) 2022-02-09

Family

ID=70457981

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054087A MA54087A (fr) 2018-11-02 2019-11-01 Sels cristallins d'un inhibiteur de la kallicréine plasmatique

Country Status (22)

Country Link
US (11) US10662160B1 (https=)
EP (1) EP3873463A4 (https=)
JP (2) JP2022505670A (https=)
KR (1) KR102810837B1 (https=)
CN (1) CN112969458A (https=)
AR (1) AR116951A1 (https=)
AU (1) AU2019374115B8 (https=)
BR (1) BR112021008249A2 (https=)
CA (1) CA3117123A1 (https=)
CL (1) CL2021001094A1 (https=)
CO (1) CO2021007172A2 (https=)
EA (1) EA202191192A1 (https=)
IL (2) IL322896A (https=)
MA (1) MA54087A (https=)
MX (1) MX2021004917A (https=)
PE (1) PE20211280A1 (https=)
PH (1) PH12021550883A1 (https=)
PY (1) PY1991831A (https=)
SG (1) SG11202103804TA (https=)
TW (1) TW202031255A (https=)
UY (1) UY38438A (https=)
WO (1) WO2020092898A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102736869B1 (ko) 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
WO2021025969A1 (en) * 2019-08-02 2021-02-11 Teva Pharmaceuticals International Gmbh Solid state forms of berotralstat
CN116375648A (zh) * 2023-03-22 2023-07-04 苏州农平科技发展有限公司 贝罗司他中间体的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
BRPI0519331A2 (pt) 2004-12-15 2009-01-20 Bristol Myers Squibb Co formas cristalina de um inibidor de fator xa
CN101495468A (zh) * 2006-07-31 2009-07-29 艾克提弗赛特制药股份有限公司 血浆激肽释放酶抑制剂
WO2008016883A2 (en) 2006-07-31 2008-02-07 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
RU2585683C2 (ru) * 2010-05-19 2016-06-10 Сандоз Аг Очистка позаконазола и промежуточных продуктов для синтеза позаконазола
US9012464B2 (en) 2010-11-25 2015-04-21 Ratiopharm Gmbh Salts and polymorphic forms of Afatinib
GB201212081D0 (en) * 2012-07-06 2012-08-22 Kalvista Pharmaceuticals Ltd New polymorph
KR102736869B1 (ko) * 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
DK4019022T3 (en) 2015-10-01 2024-02-19 Biocryst Pharm Inc Human plasma kallikrein inhibitors
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática
CN114206839B (zh) 2019-08-06 2025-03-07 拜奥克里斯特制药公司 血浆激肽释放酶抑制剂的生产规模合成

Also Published As

Publication number Publication date
CN112969458A (zh) 2021-06-15
US20250388548A1 (en) 2025-12-25
UY38438A (es) 2020-05-29
US11618733B2 (en) 2023-04-04
AR116951A1 (es) 2021-06-30
PY1991831A (es) 2020-07-03
US20250388546A1 (en) 2025-12-25
US12545646B2 (en) 2026-02-10
US20250376448A1 (en) 2025-12-11
US11117867B2 (en) 2021-09-14
US20250388545A1 (en) 2025-12-25
IL322896A (en) 2025-10-01
MX2021004917A (es) 2021-06-18
JP2022505670A (ja) 2022-01-14
US12590069B2 (en) 2026-03-31
TW202031255A (zh) 2020-09-01
WO2020092898A1 (en) 2020-05-07
US12545647B2 (en) 2026-02-10
BR112021008249A2 (pt) 2021-08-03
PH12021550883A1 (en) 2022-02-21
EP3873463A4 (en) 2022-06-22
AU2019374115B8 (en) 2025-08-07
US20240109844A1 (en) 2024-04-04
US12590068B2 (en) 2026-03-31
PE20211280A1 (es) 2021-07-19
AU2019374115B1 (en) 2025-07-17
KR20210087037A (ko) 2021-07-09
IL282454A (en) 2021-06-30
US12552750B2 (en) 2026-02-17
KR102810837B1 (ko) 2025-05-20
CO2021007172A2 (es) 2021-06-10
AU2019374115A1 (en) 2021-06-03
US20250388547A1 (en) 2025-12-25
SG11202103804TA (en) 2021-05-28
CA3117123A1 (en) 2020-05-07
EP3873463A1 (en) 2021-09-08
US20200308118A1 (en) 2020-10-01
US20220204454A1 (en) 2022-06-30
JP2024109860A (ja) 2024-08-14
US20200140389A1 (en) 2020-05-07
US20250376447A1 (en) 2025-12-11
US12344585B2 (en) 2025-07-01
EA202191192A1 (ru) 2021-09-23
US20250388549A1 (en) 2025-12-25
US12545645B2 (en) 2026-02-10
US10662160B1 (en) 2020-05-26
CL2021001094A1 (es) 2021-10-15

Similar Documents

Publication Publication Date Title
MA52493A (fr) Sels d'un inhibiteur de fgfr
EP3541807A4 (en) CRYSTALINE SHAPES OF A MAGL INHIBITOR
IL290106A (en) Crystalline form of atr inhibitor and use thereof
MA42606A (fr) Sels d'un inhibiteur de lsd1
EP3807279A4 (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF SEPIAPTERINE
EP3873463A4 (en) CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR
SG11202107225SA (en) Crystalline form of a cdk inhibitor
MA50223A (fr) Sels inhibiteurs de ferroportine
IL283860A (en) Crystalline forms and salt forms of a kinase inhibitor
EP3619208C0 (en) CRYSTALLINE FORMS OF A JAK INHIBITOR COMPOUND
IL287668A (en) Crystalline forms of a btk inhibitor
MA42780A (fr) Sels d'un inhibiteur de la kinase pim
MA56001A (fr) Formes de sel cristallin d'un inhibiteur de kinase
IL289929A (en) Crystal forms of cd73 inhibitor
DK3826982T3 (da) Anvendelse af en substitueret thiazolidinforbindelse som nitrificeringshæmmer
SG11202102110PA (en) Novel hydrochloride salt forms of a sulfonamide structured kinase inhibitor
EP3996707A4 (en) CRYSTALLINE FORMS OF PLASMACALLICREIN INHIBITORS
EP3672972A4 (en) SALT OF A COMPOUND AND CRYSTALLINE FORMS OF IT
EP3849964A4 (en) CRYSTALLINE FORMS OF A QUINAZOLE COMPOUND AND ITS HYDROCHLORIDE SALTS
HUE062106T2 (hu) Peptid-epoxiketon-immunoproteaszóma inhibitor kristályos sói
LT3891156T (lt) Tienopirimidino, kaip mcl-1 inhibitoriaus, naujos kristalinės formos
IL292847A (en) Crystalline forms of magl inhibitor
EP4045484A4 (en) SALTS OF A COMPOUND AND CRYSTALLINE FORMS THEREOF
EP3774733A4 (en) NEW SALT FORMS OF URAT-1 INHIBITORS
EP3380481A4 (en) CRYSTALLINE FORMS OF HYDROCHLORIDE SALTS OF A THIENPYRIMIDINE COMPOUND